| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Septal Nuclei | 47 | 2024 | 51 | 16.560 |
Why?
|
| Ethanol | 26 | 2024 | 306 | 6.070 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 22 | 2022 | 75 | 5.310 |
Why?
|
| Synaptic Transmission | 35 | 2024 | 147 | 5.170 |
Why?
|
| Receptors, Metabotropic Glutamate | 21 | 2024 | 30 | 4.520 |
Why?
|
| Behavior, Animal | 23 | 2024 | 215 | 4.210 |
Why?
|
| Neurons | 30 | 2024 | 863 | 3.850 |
Why?
|
| Amygdala | 21 | 2023 | 78 | 3.800 |
Why?
|
| Glutamic Acid | 25 | 2019 | 95 | 3.690 |
Why?
|
| Cocaine | 14 | 2024 | 96 | 3.450 |
Why?
|
| Mice, Inbred C57BL | 71 | 2024 | 3231 | 3.350 |
Why?
|
| Stress, Psychological | 17 | 2022 | 442 | 3.320 |
Why?
|
| Synapses | 25 | 2023 | 178 | 3.010 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 12 | 2020 | 20 | 2.940 |
Why?
|
| Excitatory Postsynaptic Potentials | 24 | 2021 | 44 | 2.750 |
Why?
|
| Animals | 134 | 2024 | 19650 | 2.730 |
Why?
|
| Corticotropin-Releasing Hormone | 11 | 2020 | 34 | 2.720 |
Why?
|
| Mice | 93 | 2024 | 10291 | 2.710 |
Why?
|
| Long-Term Potentiation | 22 | 2022 | 42 | 2.700 |
Why?
|
| Central Nervous System Depressants | 7 | 2019 | 42 | 2.650 |
Why?
|
| Hippocampus | 24 | 2023 | 246 | 2.520 |
Why?
|
| Alcohol Abstinence | 6 | 2021 | 10 | 2.410 |
Why?
|
| Endocannabinoids | 12 | 2023 | 20 | 2.380 |
Why?
|
| Alcoholism | 14 | 2023 | 310 | 2.340 |
Why?
|
| Anxiety | 15 | 2023 | 387 | 2.210 |
Why?
|
| Alcohol Drinking | 6 | 2024 | 288 | 2.070 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 8 | 2017 | 24 | 2.050 |
Why?
|
| Neuronal Plasticity | 20 | 2022 | 141 | 1.990 |
Why?
|
| Conditioning, Operant | 9 | 2024 | 26 | 1.980 |
Why?
|
| Mice, Knockout | 28 | 2024 | 1994 | 1.970 |
Why?
|
| Norepinephrine | 12 | 2022 | 98 | 1.960 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 4 | 2024 | 4 | 1.840 |
Why?
|
| Long-Term Synaptic Depression | 10 | 2019 | 15 | 1.810 |
Why?
|
| Drug-Seeking Behavior | 5 | 2018 | 7 | 1.790 |
Why?
|
| Affect | 5 | 2023 | 123 | 1.750 |
Why?
|
| Central Amygdaloid Nucleus | 4 | 2023 | 5 | 1.670 |
Why?
|
| Parabrachial Nucleus | 3 | 2024 | 3 | 1.610 |
Why?
|
| Dopamine Uptake Inhibitors | 8 | 2024 | 23 | 1.580 |
Why?
|
| Male | 89 | 2024 | 27749 | 1.480 |
Why?
|
| Cerebral Cortex | 7 | 2024 | 248 | 1.450 |
Why?
|
| Corpus Striatum | 8 | 2018 | 93 | 1.420 |
Why?
|
| Dopaminergic Neurons | 2 | 2024 | 32 | 1.360 |
Why?
|
| Extinction, Psychological | 5 | 2019 | 14 | 1.230 |
Why?
|
| Nucleus Accumbens | 6 | 2024 | 42 | 1.210 |
Why?
|
| Ketamine | 3 | 2018 | 32 | 1.180 |
Why?
|
| Depression | 5 | 2020 | 829 | 1.180 |
Why?
|
| Patch-Clamp Techniques | 15 | 2018 | 126 | 1.160 |
Why?
|
| Neural Pathways | 11 | 2024 | 95 | 1.080 |
Why?
|
| Receptor, Adenosine A2A | 2 | 2024 | 14 | 1.070 |
Why?
|
| Signal Transduction | 20 | 2024 | 2900 | 1.030 |
Why?
|
| Reward | 9 | 2024 | 83 | 1.030 |
Why?
|
| Nerve Net | 4 | 2020 | 93 | 1.000 |
Why?
|
| Glycerides | 7 | 2017 | 11 | 0.980 |
Why?
|
| Arachidonic Acids | 7 | 2017 | 23 | 0.980 |
Why?
|
| Mice, Transgenic | 19 | 2024 | 1206 | 0.940 |
Why?
|
| Substance-Related Disorders | 9 | 2022 | 687 | 0.930 |
Why?
|
| Receptors, AMPA | 7 | 2012 | 42 | 0.930 |
Why?
|
| Astrocytes | 2 | 2024 | 116 | 0.920 |
Why?
|
| Wakefulness | 1 | 2024 | 42 | 0.910 |
Why?
|
| Excitatory Amino Acid Antagonists | 10 | 2019 | 30 | 0.900 |
Why?
|
| Alcohol-Related Disorders | 2 | 2018 | 35 | 0.900 |
Why?
|
| Prefrontal Cortex | 9 | 2024 | 107 | 0.890 |
Why?
|
| Organ Culture Techniques | 9 | 2015 | 68 | 0.850 |
Why?
|
| Mood Disorders | 2 | 2018 | 69 | 0.850 |
Why?
|
| Guanfacine | 6 | 2022 | 6 | 0.850 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 3 | 2018 | 7 | 0.840 |
Why?
|
| Piperidines | 6 | 2017 | 55 | 0.830 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 7 | 2013 | 30 | 0.810 |
Why?
|
| Cyclic AMP | 9 | 2006 | 142 | 0.800 |
Why?
|
| Fear | 4 | 2021 | 65 | 0.780 |
Why?
|
| Dopamine | 6 | 2018 | 102 | 0.760 |
Why?
|
| Physical Conditioning, Animal | 1 | 2021 | 38 | 0.740 |
Why?
|
| Self Administration | 8 | 2024 | 46 | 0.730 |
Why?
|
| In Vitro Techniques | 16 | 2013 | 472 | 0.720 |
Why?
|
| Cues | 4 | 2019 | 73 | 0.710 |
Why?
|
| Substance Withdrawal Syndrome | 5 | 2024 | 119 | 0.710 |
Why?
|
| Yohimbine | 2 | 2012 | 8 | 0.710 |
Why?
|
| Receptors, GABA-A | 3 | 2013 | 23 | 0.690 |
Why?
|
| Receptors, Adrenergic, beta | 4 | 2011 | 20 | 0.690 |
Why?
|
| Social Isolation | 3 | 2024 | 29 | 0.680 |
Why?
|
| Female | 34 | 2024 | 30726 | 0.670 |
Why?
|
| Psychotropic Drugs | 2 | 2018 | 81 | 0.660 |
Why?
|
| Electric Stimulation | 13 | 2011 | 131 | 0.630 |
Why?
|
| Affective Symptoms | 1 | 2018 | 15 | 0.620 |
Why?
|
| Restraint, Physical | 5 | 2022 | 33 | 0.620 |
Why?
|
| Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2018 | 2 | 0.620 |
Why?
|
| Adrenergic Neurons | 2 | 2019 | 2 | 0.580 |
Why?
|
| Sex Characteristics | 5 | 2024 | 197 | 0.580 |
Why?
|
| Excitatory Amino Acid Agonists | 6 | 2019 | 18 | 0.580 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2015 | 805 | 0.570 |
Why?
|
| Benzodioxoles | 3 | 2017 | 13 | 0.570 |
Why?
|
| Cocaine-Related Disorders | 3 | 2024 | 82 | 0.570 |
Why?
|
| Catecholamines | 2 | 2018 | 29 | 0.560 |
Why?
|
| Basolateral Nuclear Complex | 3 | 2023 | 4 | 0.560 |
Why?
|
| Calcineurin | 5 | 2001 | 43 | 0.560 |
Why?
|
| Psychoses, Alcoholic | 1 | 2016 | 2 | 0.540 |
Why?
|
| Adaptation, Physiological | 3 | 2020 | 117 | 0.530 |
Why?
|
| Feeding Behavior | 2 | 2020 | 254 | 0.530 |
Why?
|
| Neural Inhibition | 6 | 2019 | 25 | 0.520 |
Why?
|
| Exploratory Behavior | 4 | 2011 | 33 | 0.520 |
Why?
|
| Ventral Tegmental Area | 2 | 2014 | 33 | 0.520 |
Why?
|
| Monoacylglycerol Lipases | 1 | 2016 | 2 | 0.510 |
Why?
|
| Brain | 12 | 2022 | 1488 | 0.510 |
Why?
|
| Isoproterenol | 7 | 2013 | 34 | 0.510 |
Why?
|
| Receptors, G-Protein-Coupled | 3 | 2019 | 124 | 0.510 |
Why?
|
| Nerve Tissue Proteins | 6 | 2024 | 418 | 0.500 |
Why?
|
| Disease Models, Animal | 10 | 2018 | 2050 | 0.490 |
Why?
|
| Raphe Nuclei | 1 | 2014 | 6 | 0.460 |
Why?
|
| Solitary Nucleus | 1 | 2014 | 6 | 0.460 |
Why?
|
| Photic Stimulation | 2 | 2012 | 89 | 0.450 |
Why?
|
| Adrenergic beta-Agonists | 7 | 2013 | 31 | 0.450 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 6 | 2012 | 8 | 0.430 |
Why?
|
| Parvalbumins | 2 | 2024 | 8 | 0.430 |
Why?
|
| Electrophysiology | 6 | 2009 | 87 | 0.420 |
Why?
|
| Interneurons | 3 | 2022 | 22 | 0.420 |
Why?
|
| Humans | 39 | 2024 | 59389 | 0.410 |
Why?
|
| Avoidance Learning | 2 | 2024 | 23 | 0.410 |
Why?
|
| Adrenergic alpha-2 Receptor Antagonists | 1 | 2012 | 4 | 0.400 |
Why?
|
| Periaqueductal Gray | 2 | 2024 | 4 | 0.390 |
Why?
|
| Analysis of Variance | 6 | 2011 | 589 | 0.390 |
Why?
|
| Drug Interactions | 6 | 2008 | 115 | 0.380 |
Why?
|
| Oxycodone | 2 | 2024 | 30 | 0.380 |
Why?
|
| Acoustic Stimulation | 1 | 2012 | 50 | 0.380 |
Why?
|
| Thalamus | 2 | 2024 | 64 | 0.380 |
Why?
|
| Maze Learning | 6 | 2011 | 50 | 0.380 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2003 | 205 | 0.380 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 4 | 2006 | 90 | 0.370 |
Why?
|
| Rats | 14 | 2019 | 1910 | 0.370 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 2008 | 15 | 0.370 |
Why?
|
| Pyramidal Cells | 6 | 2024 | 26 | 0.360 |
Why?
|
| Memory | 5 | 2007 | 111 | 0.360 |
Why?
|
| Calcium | 8 | 2019 | 555 | 0.360 |
Why?
|
| Sensation | 1 | 2010 | 19 | 0.350 |
Why?
|
| Adrenergic alpha-Agonists | 5 | 2009 | 20 | 0.350 |
Why?
|
| Allosteric Regulation | 3 | 2019 | 68 | 0.350 |
Why?
|
| Inhibitory Postsynaptic Potentials | 4 | 2013 | 8 | 0.340 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2010 | 9 | 0.340 |
Why?
|
| Peptides | 2 | 2012 | 549 | 0.340 |
Why?
|
| Receptors, Glutamate | 5 | 2007 | 17 | 0.340 |
Why?
|
| Cannabinoid Receptor Modulators | 1 | 2009 | 4 | 0.330 |
Why?
|
| Receptors, Adrenergic | 3 | 2018 | 7 | 0.330 |
Why?
|
| Receptors, Adrenergic, beta-1 | 3 | 2006 | 7 | 0.330 |
Why?
|
| Adenosine | 2 | 2024 | 70 | 0.320 |
Why?
|
| Presynaptic Terminals | 3 | 2009 | 37 | 0.320 |
Why?
|
| Membrane Potentials | 5 | 2019 | 137 | 0.310 |
Why?
|
| Motor Activity | 3 | 2010 | 333 | 0.310 |
Why?
|
| Receptors, Dopamine D1 | 3 | 2017 | 22 | 0.300 |
Why?
|
| Pyrimidines | 4 | 2013 | 131 | 0.300 |
Why?
|
| Aging | 4 | 2013 | 710 | 0.290 |
Why?
|
| Potassium Channel Blockers | 2 | 2005 | 24 | 0.290 |
Why?
|
| Somatostatin | 3 | 2023 | 18 | 0.290 |
Why?
|
| Phosphoprotein Phosphatases | 3 | 2006 | 41 | 0.280 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2007 | 294 | 0.280 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 2 | 2019 | 15 | 0.270 |
Why?
|
| Sex Factors | 5 | 2024 | 935 | 0.270 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2006 | 40 | 0.270 |
Why?
|
| Neuropeptide Y | 1 | 2006 | 12 | 0.270 |
Why?
|
| Phosphorylation | 9 | 2011 | 883 | 0.270 |
Why?
|
| Phenols | 3 | 2013 | 74 | 0.260 |
Why?
|
| Gene Regulatory Networks | 1 | 2007 | 147 | 0.260 |
Why?
|
| Carrier Proteins | 1 | 2010 | 697 | 0.250 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 3 | 2012 | 9 | 0.250 |
Why?
|
| Neuroglia | 2 | 1996 | 79 | 0.250 |
Why?
|
| Reinforcement Schedule | 4 | 2010 | 8 | 0.250 |
Why?
|
| Phosphatidylinositols | 3 | 1995 | 49 | 0.250 |
Why?
|
| gamma-Aminobutyric Acid | 4 | 2015 | 70 | 0.250 |
Why?
|
| N-Methylaspartate | 4 | 2007 | 14 | 0.250 |
Why?
|
| Time Factors | 7 | 2011 | 3617 | 0.240 |
Why?
|
| Proteome | 2 | 2016 | 141 | 0.240 |
Why?
|
| Housing, Animal | 1 | 2024 | 12 | 0.230 |
Why?
|
| Diffusion Tensor Imaging | 3 | 2021 | 69 | 0.230 |
Why?
|
| Fornix, Brain | 1 | 2004 | 10 | 0.230 |
Why?
|
| Optogenetics | 3 | 2024 | 22 | 0.230 |
Why?
|
| Neurophysiology | 1 | 2004 | 7 | 0.230 |
Why?
|
| Depressive Disorder | 1 | 2007 | 279 | 0.230 |
Why?
|
| Receptors, Opioid, mu | 1 | 2024 | 14 | 0.230 |
Why?
|
| Cell Death | 1 | 2006 | 271 | 0.230 |
Why?
|
| Dissection | 1 | 2004 | 45 | 0.230 |
Why?
|
| Parkinson Disease | 1 | 2006 | 125 | 0.230 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2006 | 258 | 0.220 |
Why?
|
| Lipoprotein Lipase | 3 | 2017 | 14 | 0.220 |
Why?
|
| Rats, Sprague-Dawley | 10 | 2019 | 574 | 0.220 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channels | 1 | 2024 | 29 | 0.220 |
Why?
|
| Neurodegenerative Diseases | 1 | 2006 | 134 | 0.220 |
Why?
|
| Homer Scaffolding Proteins | 2 | 2015 | 4 | 0.220 |
Why?
|
| Adaptation, Psychological | 2 | 2022 | 259 | 0.210 |
Why?
|
| Cannabinoids | 1 | 2023 | 38 | 0.210 |
Why?
|
| GTP-Binding Proteins | 2 | 2009 | 81 | 0.210 |
Why?
|
| Action Potentials | 5 | 2020 | 101 | 0.210 |
Why?
|
| Receptor, Cannabinoid, CB1 | 3 | 2023 | 10 | 0.200 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2022 | 19 | 0.200 |
Why?
|
| Diglycerides | 2 | 2014 | 23 | 0.200 |
Why?
|
| Cytoskeletal Proteins | 3 | 2024 | 196 | 0.200 |
Why?
|
| Stress, Physiological | 3 | 2010 | 185 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-fos | 2 | 2019 | 52 | 0.190 |
Why?
|
| Pharmaceutical Preparations | 1 | 2002 | 117 | 0.190 |
Why?
|
| Sleep | 2 | 2021 | 215 | 0.190 |
Why?
|
| Diet, High-Fat | 1 | 2022 | 163 | 0.180 |
Why?
|
| Theta Rhythm | 2 | 2003 | 5 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2007 | 474 | 0.180 |
Why?
|
| Morpholines | 2 | 2012 | 86 | 0.170 |
Why?
|
| Receptors, Neurotransmitter | 2 | 2007 | 17 | 0.170 |
Why?
|
| Electrophysiological Phenomena | 1 | 2020 | 20 | 0.170 |
Why?
|
| Aniline Compounds | 2 | 2013 | 35 | 0.170 |
Why?
|
| Binge Drinking | 1 | 2020 | 27 | 0.170 |
Why?
|
| Receptors, Dopamine | 2 | 2018 | 16 | 0.170 |
Why?
|
| Occipital Lobe | 1 | 2020 | 17 | 0.170 |
Why?
|
| Adrenergic Agents | 1 | 2020 | 15 | 0.170 |
Why?
|
| Neurotransmitter Agents | 2 | 2012 | 41 | 0.170 |
Why?
|
| Gene Expression | 3 | 2018 | 809 | 0.170 |
Why?
|
| Green Fluorescent Proteins | 2 | 2014 | 354 | 0.170 |
Why?
|
| Receptor, Muscarinic M5 | 1 | 2019 | 1 | 0.160 |
Why?
|
| Tissue Culture Techniques | 2 | 2018 | 31 | 0.160 |
Why?
|
| Nociception | 1 | 2019 | 9 | 0.160 |
Why?
|
| GTP-Binding Protein gamma Subunits | 1 | 2019 | 2 | 0.160 |
Why?
|
| GTP-Binding Protein beta Subunits | 1 | 2019 | 5 | 0.160 |
Why?
|
| Narcotics | 1 | 2019 | 50 | 0.160 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 428 | 0.160 |
Why?
|
| Behavior, Addictive | 1 | 2020 | 72 | 0.160 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 483 | 0.160 |
Why?
|
| Synaptosomal-Associated Protein 25 | 1 | 2019 | 10 | 0.160 |
Why?
|
| Energy Metabolism | 1 | 2021 | 359 | 0.160 |
Why?
|
| Protein Kinase C-delta | 1 | 2018 | 7 | 0.160 |
Why?
|
| Genes, fos | 1 | 2018 | 18 | 0.160 |
Why?
|
| Ovariectomy | 1 | 2018 | 96 | 0.150 |
Why?
|
| Arousal | 1 | 2018 | 41 | 0.150 |
Why?
|
| Discrimination Learning | 1 | 2018 | 11 | 0.150 |
Why?
|
| Peptide Fragments | 2 | 2013 | 400 | 0.150 |
Why?
|
| Mice, Inbred ICR | 3 | 2017 | 28 | 0.150 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 1998 | 51 | 0.140 |
Why?
|
| Anxiety Disorders | 2 | 2012 | 186 | 0.140 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 2 | 2018 | 3 | 0.140 |
Why?
|
| Opioid-Related Disorders | 1 | 2024 | 456 | 0.140 |
Why?
|
| GABA Antagonists | 2 | 2007 | 2 | 0.140 |
Why?
|
| Cycloleucine | 5 | 1995 | 6 | 0.140 |
Why?
|
| Social Behavior | 1 | 2017 | 87 | 0.140 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 121 | 0.140 |
Why?
|
| Luminescence | 1 | 2016 | 18 | 0.130 |
Why?
|
| Tyrosine 3-Monooxygenase | 2 | 2014 | 33 | 0.130 |
Why?
|
| Luciferases | 1 | 2016 | 106 | 0.130 |
Why?
|
| Protein Interaction Maps | 1 | 2016 | 33 | 0.130 |
Why?
|
| Gene Knockdown Techniques | 2 | 2013 | 194 | 0.130 |
Why?
|
| Calcium Channels, L-Type | 2 | 2007 | 24 | 0.130 |
Why?
|
| Cell Communication | 1 | 1996 | 124 | 0.130 |
Why?
|
| Evoked Potentials | 4 | 2005 | 33 | 0.130 |
Why?
|
| Colforsin | 3 | 2005 | 24 | 0.130 |
Why?
|
| Mice, 129 Strain | 1 | 2015 | 37 | 0.130 |
Why?
|
| Anti-Anxiety Agents | 1 | 2015 | 31 | 0.120 |
Why?
|
| Gene Knock-In Techniques | 2 | 2019 | 34 | 0.120 |
Why?
|
| Transfection | 4 | 2009 | 675 | 0.120 |
Why?
|
| Enzyme Activation | 5 | 2007 | 359 | 0.120 |
Why?
|
| Miniature Postsynaptic Potentials | 1 | 2014 | 1 | 0.120 |
Why?
|
| Electric Capacitance | 1 | 2014 | 3 | 0.120 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2006 | 147 | 0.120 |
Why?
|
| Potassium Channels | 2 | 2006 | 53 | 0.110 |
Why?
|
| Electric Impedance | 1 | 2014 | 35 | 0.110 |
Why?
|
| Proteomics | 1 | 2016 | 263 | 0.110 |
Why?
|
| Systems Biology | 1 | 2014 | 29 | 0.110 |
Why?
|
| Picrotoxin | 2 | 2019 | 5 | 0.110 |
Why?
|
| Nervous System | 1 | 2014 | 69 | 0.110 |
Why?
|
| Corticosterone | 2 | 2011 | 22 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 3 | 2001 | 735 | 0.110 |
Why?
|
| Peptides, Cyclic | 1 | 2013 | 20 | 0.100 |
Why?
|
| Immune System | 1 | 2014 | 129 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 2 | 2014 | 650 | 0.100 |
Why?
|
| Models, Neurological | 1 | 2013 | 79 | 0.100 |
Why?
|
| Orexin Receptors | 1 | 2012 | 2 | 0.100 |
Why?
|
| Receptors, Neuropeptide | 1 | 2012 | 3 | 0.100 |
Why?
|
| Orexins | 1 | 2012 | 5 | 0.100 |
Why?
|
| Adenylyl Cyclases | 1 | 2012 | 21 | 0.100 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 284 | 0.100 |
Why?
|
| Self Stimulation | 1 | 2012 | 2 | 0.100 |
Why?
|
| Benzoxazoles | 1 | 2012 | 5 | 0.100 |
Why?
|
| Receptors, Cannabinoid | 2 | 2023 | 6 | 0.100 |
Why?
|
| Mental Recall | 1 | 2012 | 88 | 0.100 |
Why?
|
| Neuropeptides | 1 | 2012 | 83 | 0.100 |
Why?
|
| Rodentia | 2 | 2023 | 21 | 0.090 |
Why?
|
| Threonine | 1 | 2011 | 15 | 0.090 |
Why?
|
| Acetanilides | 1 | 2011 | 3 | 0.090 |
Why?
|
| Thioglycolates | 1 | 2011 | 7 | 0.090 |
Why?
|
| Phosphoserine | 2 | 2006 | 10 | 0.090 |
Why?
|
| Biophysics | 1 | 2011 | 41 | 0.090 |
Why?
|
| Brain Chemistry | 2 | 2008 | 77 | 0.090 |
Why?
|
| Antidepressive Agents | 3 | 2019 | 212 | 0.090 |
Why?
|
| Auditory Perception | 1 | 2010 | 33 | 0.090 |
Why?
|
| Blotting, Western | 5 | 2013 | 583 | 0.090 |
Why?
|
| Pattern Recognition, Visual | 1 | 2010 | 37 | 0.090 |
Why?
|
| Vasoconstrictor Agents | 1 | 2010 | 64 | 0.090 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2010 | 6 | 0.080 |
Why?
|
| Recombinant Proteins | 2 | 2005 | 689 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2012 | 327 | 0.080 |
Why?
|
| Reactive Oxygen Species | 2 | 2013 | 205 | 0.080 |
Why?
|
| Interpersonal Relations | 1 | 2011 | 150 | 0.080 |
Why?
|
| Benzoxazines | 1 | 2009 | 10 | 0.080 |
Why?
|
| Naphthalenes | 1 | 2009 | 18 | 0.080 |
Why?
|
| Superior Cervical Ganglion | 1 | 2009 | 9 | 0.080 |
Why?
|
| Organophosphonates | 1 | 2009 | 21 | 0.080 |
Why?
|
| Hemagglutinins | 1 | 2009 | 17 | 0.080 |
Why?
|
| Flupenthixol | 1 | 2009 | 1 | 0.080 |
Why?
|
| Clonidine | 1 | 2009 | 24 | 0.080 |
Why?
|
| Dopamine Antagonists | 1 | 2009 | 15 | 0.080 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 2007 | 33 | 0.080 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2008 | 20 | 0.080 |
Why?
|
| 6-Cyano-7-nitroquinoxaline-2,3-dione | 1 | 2008 | 5 | 0.080 |
Why?
|
| Methoxyhydroxyphenylglycol | 1 | 2008 | 8 | 0.080 |
Why?
|
| Asthma | 1 | 2013 | 460 | 0.080 |
Why?
|
| Genotype | 1 | 2010 | 617 | 0.080 |
Why?
|
| Food Preferences | 1 | 2009 | 50 | 0.080 |
Why?
|
| Prosencephalon | 3 | 2012 | 37 | 0.080 |
Why?
|
| Calcineurin Inhibitors | 2 | 2006 | 23 | 0.080 |
Why?
|
| Imidazoles | 1 | 2008 | 77 | 0.070 |
Why?
|
| Locomotion | 1 | 2009 | 111 | 0.070 |
Why?
|
| Neurotransmitter Transport Proteins | 1 | 2007 | 1 | 0.070 |
Why?
|
| Receptors, Oncostatin M | 1 | 2007 | 1 | 0.070 |
Why?
|
| HEK293 Cells | 3 | 2016 | 587 | 0.070 |
Why?
|
| Receptors, Cholinergic | 1 | 2007 | 19 | 0.070 |
Why?
|
| Adenosine Triphosphate | 2 | 2007 | 289 | 0.070 |
Why?
|
| Genetic Linkage | 1 | 2007 | 93 | 0.070 |
Why?
|
| Kinetics | 1 | 2009 | 751 | 0.070 |
Why?
|
| Receptors, GABA-B | 2 | 2009 | 2 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2007 | 718 | 0.070 |
Why?
|
| Kidney | 2 | 2009 | 414 | 0.070 |
Why?
|
| Calmodulin | 1 | 2007 | 19 | 0.070 |
Why?
|
| Genes, Reporter | 1 | 2007 | 241 | 0.070 |
Why?
|
| Urocortins | 1 | 2006 | 5 | 0.070 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2006 | 52 | 0.070 |
Why?
|
| Pyridazines | 1 | 2006 | 8 | 0.070 |
Why?
|
| Magnesium | 2 | 2007 | 52 | 0.070 |
Why?
|
| Benzothiadiazines | 1 | 2006 | 1 | 0.060 |
Why?
|
| 2-Amino-5-phosphonovalerate | 1 | 2006 | 1 | 0.060 |
Why?
|
| Marine Toxins | 1 | 2006 | 2 | 0.060 |
Why?
|
| Egtazic Acid | 1 | 2006 | 8 | 0.060 |
Why?
|
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 2006 | 6 | 0.060 |
Why?
|
| Species Specificity | 2 | 2010 | 329 | 0.060 |
Why?
|
| Protein Phosphatase 1 | 1 | 2006 | 16 | 0.060 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2006 | 12 | 0.060 |
Why?
|
| Oxazoles | 1 | 2006 | 10 | 0.060 |
Why?
|
| Protein Phosphatase 2 | 1 | 2006 | 10 | 0.060 |
Why?
|
| Substantia Nigra | 1 | 2006 | 14 | 0.060 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2007 | 135 | 0.060 |
Why?
|
| RNA, Messenger | 3 | 2007 | 1466 | 0.060 |
Why?
|
| Cyclosporine | 1 | 2006 | 76 | 0.060 |
Why?
|
| Tetrodotoxin | 1 | 2005 | 9 | 0.060 |
Why?
|
| Hydrolysis | 3 | 1995 | 141 | 0.060 |
Why?
|
| Sodium Channel Blockers | 1 | 2005 | 10 | 0.060 |
Why?
|
| Mice, Inbred DBA | 2 | 2019 | 84 | 0.060 |
Why?
|
| Tetraethylammonium | 1 | 2005 | 8 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2007 | 236 | 0.060 |
Why?
|
| Brimonidine Tartrate | 1 | 2004 | 2 | 0.060 |
Why?
|
| 8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 2004 | 2 | 0.060 |
Why?
|
| Quinpirole | 1 | 2004 | 5 | 0.060 |
Why?
|
| GABA Agonists | 1 | 2004 | 5 | 0.060 |
Why?
|
| Baclofen | 1 | 2004 | 2 | 0.060 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2004 | 12 | 0.060 |
Why?
|
| Radioimmunoassay | 1 | 2004 | 63 | 0.060 |
Why?
|
| Dopamine Agonists | 1 | 2004 | 20 | 0.060 |
Why?
|
| Radio Frequency Identification Device | 1 | 2024 | 10 | 0.060 |
Why?
|
| Quinoxalines | 1 | 2004 | 35 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2007 | 814 | 0.060 |
Why?
|
| Phenotype | 2 | 2019 | 1137 | 0.060 |
Why?
|
| Connectome | 1 | 2024 | 29 | 0.060 |
Why?
|
| Protein Binding | 3 | 2019 | 1555 | 0.060 |
Why?
|
| Neurotoxins | 2 | 1995 | 20 | 0.060 |
Why?
|
| Age Factors | 2 | 2011 | 1504 | 0.050 |
Why?
|
| rap1 GTP-Binding Proteins | 1 | 2003 | 3 | 0.050 |
Why?
|
| Amino Acids, Cyclic | 1 | 2003 | 2 | 0.050 |
Why?
|
| Adrenergic Antagonists | 1 | 2003 | 3 | 0.050 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2003 | 4 | 0.050 |
Why?
|
| Valine | 1 | 2003 | 31 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 841 | 0.050 |
Why?
|
| Protein Kinase C | 2 | 1995 | 98 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2003 | 44 | 0.050 |
Why?
|
| GABA-A Receptor Antagonists | 1 | 2003 | 3 | 0.050 |
Why?
|
| Drinking | 1 | 2023 | 13 | 0.050 |
Why?
|
| Gene Expression Regulation | 3 | 2001 | 1552 | 0.050 |
Why?
|
| Body Weight | 1 | 2024 | 368 | 0.050 |
Why?
|
| Mice, Obese | 1 | 2022 | 80 | 0.050 |
Why?
|
| Models, Biological | 1 | 2007 | 1143 | 0.050 |
Why?
|
| Genetics, Behavioral | 1 | 2001 | 11 | 0.050 |
Why?
|
| Somatosensory Cortex | 1 | 2021 | 19 | 0.050 |
Why?
|
| Cell Compartmentation | 1 | 2001 | 35 | 0.050 |
Why?
|
| Dentate Gyrus | 2 | 2001 | 11 | 0.050 |
Why?
|
| Transcriptome | 1 | 2024 | 340 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2001 | 136 | 0.050 |
Why?
|
| Cell Line | 1 | 2005 | 1983 | 0.050 |
Why?
|
| Learning | 1 | 2002 | 171 | 0.040 |
Why?
|
| Transgenes | 2 | 2001 | 177 | 0.040 |
Why?
|
| Protein Subunits | 1 | 2001 | 165 | 0.040 |
Why?
|
| Memory, Short-Term | 1 | 2001 | 59 | 0.040 |
Why?
|
| Young Adult | 2 | 2021 | 4272 | 0.040 |
Why?
|
| Cyclooxygenase 2 | 1 | 2020 | 73 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2023 | 2055 | 0.040 |
Why?
|
| Freezing Reaction, Cataleptic | 1 | 2019 | 1 | 0.040 |
Why?
|
| Conditioning, Classical | 1 | 2019 | 5 | 0.040 |
Why?
|
| Anhedonia | 1 | 2019 | 6 | 0.040 |
Why?
|
| Echo-Planar Imaging | 1 | 2020 | 33 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 1999 | 51 | 0.040 |
Why?
|
| Oxidation-Reduction | 2 | 2013 | 303 | 0.040 |
Why?
|
| Kynurenic Acid | 1 | 2019 | 2 | 0.040 |
Why?
|
| Propranolol | 1 | 2019 | 21 | 0.040 |
Why?
|
| Dendrites | 1 | 1999 | 56 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2004 | 1559 | 0.040 |
Why?
|
| Macromolecular Substances | 1 | 1999 | 160 | 0.040 |
Why?
|
| Pyrrolidinones | 1 | 1998 | 11 | 0.040 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 1998 | 27 | 0.040 |
Why?
|
| Exocytosis | 1 | 2019 | 59 | 0.040 |
Why?
|
| Adrenergic alpha-1 Receptor Agonists | 1 | 2018 | 3 | 0.040 |
Why?
|
| Tetracycline | 1 | 1998 | 22 | 0.040 |
Why?
|
| Locus Coeruleus | 1 | 2018 | 21 | 0.040 |
Why?
|
| Resorcinols | 2 | 1995 | 5 | 0.040 |
Why?
|
| Limbic System | 1 | 2018 | 27 | 0.040 |
Why?
|
| Carcinogenicity Tests | 1 | 1998 | 2 | 0.040 |
Why?
|
| Melitten | 1 | 1998 | 2 | 0.040 |
Why?
|
| Glycine | 2 | 1995 | 46 | 0.040 |
Why?
|
| Single-Strand Specific DNA and RNA Endonucleases | 1 | 1998 | 5 | 0.040 |
Why?
|
| Stimulation, Chemical | 1 | 1998 | 18 | 0.040 |
Why?
|
| Recurrence | 1 | 2020 | 602 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1051 | 0.040 |
Why?
|
| Mice, Inbred CBA | 1 | 1998 | 83 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2020 | 486 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1998 | 178 | 0.040 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 1998 | 47 | 0.040 |
Why?
|
| Protein Precursors | 1 | 1998 | 75 | 0.040 |
Why?
|
| Neoplasms, Experimental | 1 | 1998 | 75 | 0.040 |
Why?
|
| Bacterial Proteins | 1 | 2003 | 737 | 0.040 |
Why?
|
| Choice Behavior | 1 | 2018 | 78 | 0.040 |
Why?
|
| Mice, Nude | 1 | 1998 | 258 | 0.040 |
Why?
|
| Adolescent | 2 | 2020 | 5838 | 0.040 |
Why?
|
| Mice, Mutant Strains | 1 | 1998 | 297 | 0.030 |
Why?
|
| Glutamates | 1 | 2017 | 13 | 0.030 |
Why?
|
| Light | 1 | 2018 | 198 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 1998 | 450 | 0.030 |
Why?
|
| Dronabinol | 1 | 2017 | 31 | 0.030 |
Why?
|
| Batrachoidiformes | 1 | 2016 | 1 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 1998 | 111 | 0.030 |
Why?
|
| Subcellular Fractions | 2 | 2009 | 68 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2016 | 39 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2017 | 157 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 847 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 2 | 2009 | 107 | 0.030 |
Why?
|
| Underage Drinking | 1 | 2016 | 5 | 0.030 |
Why?
|
| Trans-Activators | 1 | 1998 | 300 | 0.030 |
Why?
|
| Cell Division | 1 | 1998 | 443 | 0.030 |
Why?
|
| Resilience, Psychological | 1 | 2017 | 55 | 0.030 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2016 | 75 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 347 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 1998 | 297 | 0.030 |
Why?
|
| Thapsigargin | 1 | 1995 | 17 | 0.030 |
Why?
|
| Calcium-Transporting ATPases | 1 | 1995 | 7 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2016 | 526 | 0.030 |
Why?
|
| Terpenes | 1 | 1995 | 25 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2016 | 392 | 0.030 |
Why?
|
| Intracellular Membranes | 1 | 1995 | 50 | 0.030 |
Why?
|
| Ibotenic Acid | 1 | 1994 | 1 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2009 | 2092 | 0.030 |
Why?
|
| Obesity | 1 | 2022 | 1166 | 0.030 |
Why?
|
| Autism Spectrum Disorder | 1 | 2017 | 175 | 0.030 |
Why?
|
| Rest | 1 | 2014 | 44 | 0.030 |
Why?
|
| Adult | 2 | 2021 | 15681 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 2013 | 28 | 0.030 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 1993 | 23 | 0.030 |
Why?
|
| Calcium Signaling | 1 | 2014 | 153 | 0.030 |
Why?
|
| NADPH Oxidases | 1 | 2013 | 67 | 0.030 |
Why?
|
| Drug Resistance | 2 | 2009 | 95 | 0.030 |
Why?
|
| Benzylamines | 1 | 2013 | 30 | 0.030 |
Why?
|
| Ovalbumin | 1 | 2013 | 116 | 0.030 |
Why?
|
| Receptors, Purinergic | 1 | 1993 | 6 | 0.030 |
Why?
|
| Bronchi | 1 | 2013 | 82 | 0.030 |
Why?
|
| Kindling, Neurologic | 1 | 1992 | 1 | 0.030 |
Why?
|
| Adenosine Deaminase | 1 | 1993 | 17 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 191 | 0.030 |
Why?
|
| Drug Synergism | 1 | 1993 | 132 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2013 | 120 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 1998 | 628 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1992 | 150 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 2012 | 105 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 1992 | 88 | 0.020 |
Why?
|
| Alanine | 1 | 1992 | 49 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 170 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2012 | 46 | 0.020 |
Why?
|
| Proteins | 1 | 1998 | 730 | 0.020 |
Why?
|
| Gene-Environment Interaction | 1 | 2012 | 48 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 1998 | 808 | 0.020 |
Why?
|
| Neurogenesis | 1 | 2012 | 60 | 0.020 |
Why?
|
| Small Molecule Libraries | 1 | 2012 | 55 | 0.020 |
Why?
|
| Sensory Gating | 1 | 2011 | 2 | 0.020 |
Why?
|
| High-Throughput Screening Assays | 1 | 2012 | 74 | 0.020 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2011 | 8 | 0.020 |
Why?
|
| Anilides | 1 | 2011 | 17 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 267 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2012 | 89 | 0.020 |
Why?
|
| Dendritic Spines | 1 | 2010 | 11 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 651 | 0.020 |
Why?
|
| Protein Kinase C-epsilon | 1 | 2009 | 12 | 0.020 |
Why?
|
| Doxycycline | 2 | 2001 | 42 | 0.020 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2009 | 7 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 2009 | 52 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2009 | 100 | 0.020 |
Why?
|
| Membrane Microdomains | 1 | 2009 | 49 | 0.020 |
Why?
|
| Sympathetic Nervous System | 1 | 2009 | 34 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2012 | 661 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2009 | 230 | 0.020 |
Why?
|
| Integrases | 1 | 2009 | 36 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2009 | 217 | 0.020 |
Why?
|
| Biogenic Monoamines | 1 | 2008 | 5 | 0.020 |
Why?
|
| Neostriatum | 1 | 2008 | 25 | 0.020 |
Why?
|
| Endocytosis | 1 | 2009 | 149 | 0.020 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2008 | 34 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2008 | 225 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2007 | 23 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2009 | 868 | 0.020 |
Why?
|
| Mutation | 2 | 2007 | 2456 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2007 | 76 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2007 | 67 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2007 | 152 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2007 | 188 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 2006 | 29 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2007 | 554 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 197 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 836 | 0.010 |
Why?
|
| RNA Interference | 1 | 2007 | 590 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2003 | 7 | 0.010 |
Why?
|
| Tetanus | 1 | 2003 | 5 | 0.010 |
Why?
|
| Sialoglycoproteins | 1 | 2003 | 21 | 0.010 |
Why?
|
| Metalloproteins | 1 | 2003 | 13 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2003 | 27 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 1368 | 0.010 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2003 | 51 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2003 | 214 | 0.010 |
Why?
|
| Middle Aged | 1 | 2020 | 16314 | 0.010 |
Why?
|
| Reaction Time | 1 | 2003 | 119 | 0.010 |
Why?
|
| Prognosis | 1 | 2007 | 1597 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2003 | 128 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2007 | 858 | 0.010 |
Why?
|
| Form Perception | 1 | 2001 | 5 | 0.010 |
Why?
|
| Antirheumatic Agents | 1 | 2003 | 214 | 0.010 |
Why?
|
| Rolipram | 1 | 1998 | 3 | 0.010 |
Why?
|
| Cyclopropanes | 1 | 1995 | 50 | 0.010 |
Why?
|
| Adenylyl Cyclase Inhibitors | 1 | 1994 | 8 | 0.010 |
Why?
|
| Phospholipase D | 1 | 1994 | 6 | 0.010 |
Why?
|
| Cerebellar Nuclei | 1 | 1992 | 4 | 0.010 |
Why?
|